We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer reaffirmed its 2026 outlook as newer medicines helped offset another sharp decline in Covid product sales.

Q1 2026 Management View Pfizer reported a Q1 it framed as operationally strong, with Chairman and CEO Albert Bourla saying, "We've had a strong start to the year. Our business continues to perform ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer PFE reported fourth-quarter earnings ahead of our expectations, largely due to lower-than-expected research and development spending. However, we don’t expect this will continue, so there is no ...

Q1 earnings May 4: analyst EPS/revenue estimates, 2026 guidance focus, oncology & obesity pipeline catalysts, and cost cuts.

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...